ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO136

Type 1 Interferon Is Associated with Kidney Dysfunction in Type 2 Diabetes

Session Information

Category: Diabetes

  • 503 Diabetes Mellitus and Obesity: Translational

Authors

  • Conway, James, MedImmune, Gaithersburg, Maryland, United States
  • Eichinger, Felix H., University of Michigan, Ann Arbor, Michigan, United States
  • Godfrey, Brad A., University of Michigan, Ann Arbor, Michigan, United States
  • Nair, Viji, University of Michigan, Ann Arbor, Michigan, United States
  • Reznichenko, Anna, AstraZeneca, Molndal, Sweden
  • Slidel, Tim, MedImmune, Gaithersburg, Maryland, United States
  • Cohen, Clemens D., Klinikum Munchen, Munchen, Germany
  • Higgs, Brandon W, MedImmune, Gaithersburg, Maryland, United States
  • Moreno Quinn, Carol Patricia, MedImmune, Gaithersburg, Maryland, United States
  • Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
Background

Type I interferon (IFN) is linked to the pathogenesis of autoimmune and inflammatory diseases known as interferonopathies. A portion of patients show aberrant type I IFN signaling, which can be measured by a gene expression signature composed of IFN-inducible genes (IFNGS). Chronic kidney disease (CKD) is characterized by chronic inflammation and interstitial fibrosis, yet little is known regarding type I IFN signaling in type 2 diabetics (T2D) with diabetic nephropathy (DN). Here we evaluated a type I IFNGS in these patients and identified an association with immune response and kidney dysfunction.

Methods

Tissue from human glomeruli (DN, n1=12), tubulointerstitium from two independent patient sets (DN; n1=17, n2=31), and living donors (n1=46) were obtained from the European Renal cDNA Bank and profiled by Affymetrix array. Gene-set variation analysis (GSVA) quantified a 21-gene type I IFNGS identified by Yao Y et al (PMID: 20948567) and other function-specific signatures. Patients were assigned to type I IFN-low or IFN-high groups based on median GSVA score. Gene signatures for which IFN-high patients differed from IFN-low were identified. P-values were adjusted for sex and age. A Fisher’s combined probability was applied to summarize both studies (pchi).

Results

Type I IFNGS was elevated in the tubulointerstitium (pchi=1.3x10-4), but not the glomeruli of DN patients compared to living donors. IFN-high patients associated with lower glomerular filtration rate (GFR) compared to IFN-low patients (pchi=0.02). Although a high collagen signature associated with decreased GFR (pchi=0.001), it did not correlate with type I IFNGS, suggesting an independent mechanism. IFN-high patients displayed increased T cell activation (pchi=6.6x10-6), TLR4 signaling (pchi=5.7x10-5) and innate immune response (pchi=1.9x10-5).

Conclusion

A significant decrease in GFR was observed in T2D patients with elevated Type I IFN signaling, which was also linked to increases in immune response signatures. This link between type I IFN signaling and kidney dysfunction may inform on patient selection for therapies targeting immune response pathways. This hypothesis should be confirmed in an independent study.

Funding

  • Commercial Support